Harvard Management Company’s Revolution Medicines RVMD Stock Holding History

Harvard Management Company’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-315,550	Closed	-$6.83M	–	47
2023 Q1	$6.83M	Sell	315,550 -354,832	-53%	-$8.74M	0.72%	21
2022 Q4	$16M	Hold	670,382	–	–	1.98%	7
2022 Q3	$13.2M	Hold	670,382	–	–	1.64%	9
2022 Q2	$13.1M	Hold	670,382	–	–	1.51%	8
2022 Q1	$17.1M	Hold	670,382	–	–	1.73%	7
2021 Q4	$16.9M	Hold	670,382	–	–	1.58%	10
2021 Q3	$18.4M	Hold	670,382	–	–	1.08%	13
2021 Q2	$21.3M	Hold	670,382	–	–	1.22%	15
2021 Q1	$30.8M	Hold	670,382	–	–	1.72%	12
2020 Q4	$26.5M	Hold	670,382	–	–	1.44%	10
2020 Q3	$23.3M	Hold	670,382	–	–	1.28%	9
2020 Q2	$21.2M	Hold	670,382	–	–	1.81%	7
2020 Q1	$14.7M	Buy	+670,382	New	+$18.6M	2.3%	8

Other funds holding RVMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Harvard Management Company's RVMD Position: Q2 2023 in Review

Harvard Management Company sold out of Revolution Medicines (RVMD) in Q2 2023, closing a stake of 315,550 shares — an estimated $6.83M sold.

Harvard Management Company first reported a position in RVMD in Q1 2020 and held it in 13 quarters. The position peaked at $30.8M in Q1 2021. 139 funds tracked by Wall St. Rank hold RVMD as of Q2 2023.

Harvard Management Company reported no remaining Revolution Medicines position as of Q2 2023 after selling out during the quarter.
Harvard Management Company sold 315,550 Revolution Medicines shares in Q2 2023, an estimated $6.83M.
Harvard Management Company first reported a position in Revolution Medicines in Q1 2020 and held it in 13 quarters.
Harvard Management Company's Revolution Medicines position peaked at $30.8M in Q1 2021.
139 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2023.

Based on Harvard Management Company's 13F filing for Q2 2023, filed 11 Aug 2023.